Sanofi And Hengrui To Go To Court Again
This article was originally published in PharmAsia News
Executive Summary
In response to the verdict of non-patent infringement of Hengrui's use of docetaxel in China, Sanofi-Aventis is likely to appeal to the Beijing Number One Intermediate People's Court to further fight for its patent rights. The Greater China office says that it cannot comment on the case now but states that Sanofi holds the patent for docetaxel worldwide and its team of lawyers is preparing the necessary legal documents. Industry observers believe Sanofi is not likely to give up its fight for the patent as Taxotere, its key antitumor product using docetaxel, fetches a lucrative profit. (Click here for more - Chinese Language)